Pilot study of RTB101 as COVID-19 prophylaxis in older adults

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2019
    2024
  • Known Financial Commitments (USD)

    $659,614
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    JOAN B MANNICK
  • Research Location

    United States of America
  • Lead Research Institution

    RESTORBIO INC
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Older adults (65 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

AbstractGiven the elevated mortality of COVID-19 infections in older adults (Wu et al 2020), there is anurgent need to evaluate medicines that may prevent severe disease in these vulnerablepatients. Inhibition of targets downstream of target of rapamycin complex 1 (TORC1) wasreported to upregulate pan-antiviral gene expression and protect mice from a viral respiratorytract infection (RTI) (York AG et al. 2015). Importantly, RTB101 was also observed toupregulate interferon-stimulated pan-antiviral gene expression, decrease the levels ofinflammatory cytokines in serum, and decrease the incidence and severity of viral respiratorytract infections including coronavirus infections when given as prophylaxis during winter coldand flu season to older adults (Mannick et al. 2018, Mannick et al., 2019). Therefore wehypothesize that RTB101 will decrease the incidence and severity of COVID-19 when given asprophylaxis to older adults. Before undertaking a large well-powered trial for this indication, wepropose to undertake a pilot study to determine the feasibility of recruiting, consenting,screening and randomizing quarantined outpatient populations of older adults who are predictedto be at increased risk of developing COVID-19 (Specific Aim 1), assess whether COVID-19symptoms can be tracked using an eDiary in older adults (Specific Aim 2), and obtainpreliminary data on the incidence and severity of COVID-19 in subjects treated with RTB101 ascompared to placebo (Specific Aim 3). The data generated in the trial will be used to helpoptimize the study design of a larger adequately powered study to determine if RTB101 iseffective as COVID-19 prophylaxis in the older adults.References1. Mannick, J. B., Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K et al. (2018) TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 10, doi:10.1126/scitranslmed.aaq1564.2. Mannick et al, (abstract) IDWeek, 2019.3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24.4. York AG, Williams KJ, Argus JP, Zhou QD, Brar G, et al. (2015) Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling. Cell. 163(7):1716-29.